Top 5 Drug Type | Count |
---|---|
Small molecule drug | 26 |
Monoclonal antibody | 4 |
Diagnostic radiopharmaceuticals | 3 |
Hematopoietic stem cell therapy | 1 |
Fusion protein | 1 |
Target |
Mechanism PSMA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Dec 2020 |
Target |
Mechanism c-Met inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 May 2020 |
Mechanism ALK inhibitors [+4] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date18 Jun 2019 |
Start Date15 Feb 2030 |
Sponsor / Collaborator |
Start Date01 Jul 2027 |
Sponsor / Collaborator |
Start Date01 Jul 2026 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Gallium GA-68 Gozetotide ( PSMA ) | Prostatic Cancer More | Approved |
BLI-1008 ( NET ) | Attention Deficit Disorder With Hyperactivity More | NDA/BLA |
Psilocybin ( 5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor ) | Depression More | Phase 2 |
AAV2-GDNF ( GDNF family ) | Parkinson Disease More | Phase 2 |
TCRαβ/CD19 depleted HCT ( CD19 x TCR ) | Neoplasms More | Phase 2 |